News

Press Releases

Press lease

Katie Baumer
Communications and Social Media Manager, AAPS
+1.703.248.4772 direct
BaumerK@aaps.org 

 

2016-11-13

AAPS Announces Nine Fellowships, One of the Highest Organizational Honors

Nine Fellows Cover Research Ranging From Cancer Treatment to Improved Vaccines 

DENVER. (November 13, 2016)–The American Association of Pharmaceutical Scientists (AAPS) is pleased to announce the elevation of nine recipients to Fellow, one of the highest honors given to members of the association. Each year, AAPS elevates a few members to Fellow in recognition of their professional excellence in fields relevant to AAPS’s mission: to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health.

Each Fellow has demonstrated a sustained level of superior and distinguished professional achievement and contributions in fields related to this mission. Fellows are nominated by supporters, selected by a committee of their peers, and elevated by AAPS’ Executive Council.

Arvind Kumar Bansal, Ph.D.
National Institute of Pharmaceutical Education and Research (NIPER), India
Bansal develops technologies to improve water solubility of medicines so that they are more effective for patients.

Ruggero Bettini, Ph.D.
University of Parma, Italy
Bettini has developed platform systems for better oral controlled drug delivery. He is currently developing medications in form of powder for the administration of antimicrobial drugs to the lung.

Joan Korth-Bradley, Ph.D., Pharm.D.
Pfizer, Inc.
Korth-Bradley has implemented methods at Pfizer to study how very sick people absorb and eliminate medications. This information is then used to inform doctors and pharmacists about how to adjust doses so that sick people get correct dosage.

Andrew Coop, Ph.D.
University of Maryland School of Pharmacy
Coop develops morphine-like painkillers to which people cannot become addicted. Educationally, Coop aims to train the next generation of pharmaceutical scientists to honor and follow the mission of AAPS.

Barbara Davit, Ph.D., J.D.
Merck & Co., Inc.
Davit works on a number of programs developing drugs for unmet medical needs. Her programs include drugs to treat Hepatitis C disease, HIV, cancer, and neurological disorders such as psychosis.

Wim Jiskoot, Ph.D.
Leiden University, Netherlands
Jiskoot is studying how to make better vaccines and how to better stabilize protein drugs.

Thomas Schmittgen, Ph.D.
University of Florida
Schmittgen is developing new strategies to treat and detect cancer. One part of his work has been to develop an assay for the early detection of pancreatic cancer that is currently under commercial development.

Ronald Smith, Ph.D.
Merck & Co., Inc.
Smith designs and develops new drug products incorporating advanced technologies that deliver improved benefits for patients.

Changquan Sun, Ph.D.
University of Minnesota
Sun works with low dose drugs delivered in the form of oral tablets, and tries to solve the problems which may occur in the manufacturing of high potency drugs and provide long term stability of drug concentration in blood.

For more information about AAPS Fellows, visit http://www.aaps.org/Awards/.

# # #

About AAPS: The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 9,000 members employed in academia, industry, government, and other research institutes worldwide. Founded in 1986, AAPS advances the capacity of pharmaceutical scientists to develop products and therapies that improve global health. Visit www.aaps.org today and follow us on Twitter and Facebook, hashtag #AAPS.